Nanjing Vishee Medical Technology Co Ltd (688580) - Net Assets
Based on the latest financial reports, Nanjing Vishee Medical Technology Co Ltd (688580) has net assets worth CN¥1.76 Billion CNY (≈ $256.88 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.86 Billion ≈ $272.61 Million USD) and total liabilities (CN¥107.49 Million ≈ $15.73 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Nanjing Vishee Medical Technology Co Ltd (688580) total assets for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.76 Billion |
| % of Total Assets | 94.23% |
| Annual Growth Rate | 36.98% |
| 5-Year Change | 10.44% |
| 10-Year Change | 1332.41% |
| Growth Volatility | 121.16 |
Nanjing Vishee Medical Technology Co Ltd - Net Assets Trend (2013–2025)
This chart illustrates how Nanjing Vishee Medical Technology Co Ltd's net assets have evolved over time, based on quarterly financial data. Check Nanjing Vishee Medical Technology Co Ltd tangible equity quality to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Nanjing Vishee Medical Technology Co Ltd (2013–2025)
The table below shows the annual net assets of Nanjing Vishee Medical Technology Co Ltd from 2013 to 2025. For live valuation and market cap data, see Nanjing Vishee Medical Technology Co Ltd market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.69 Billion ≈ $247.75 Million |
+4.03% |
| 2024-12-31 | CN¥1.63 Billion ≈ $238.15 Million |
+0.04% |
| 2023-12-31 | CN¥1.63 Billion ≈ $238.05 Million |
+6.42% |
| 2022-12-31 | CN¥1.53 Billion ≈ $223.67 Million |
-0.29% |
| 2021-12-31 | CN¥1.53 Billion ≈ $224.34 Million |
+8.65% |
| 2020-12-31 | CN¥1.41 Billion ≈ $206.47 Million |
+453.62% |
| 2019-12-31 | CN¥254.86 Million ≈ $37.29 Million |
+29.93% |
| 2018-12-31 | CN¥196.16 Million ≈ $28.70 Million |
+27.85% |
| 2017-12-31 | CN¥153.42 Million ≈ $22.45 Million |
+29.81% |
| 2016-12-31 | CN¥118.20 Million ≈ $17.30 Million |
+11.24% |
| 2015-12-31 | CN¥106.25 Million ≈ $15.55 Million |
+72.37% |
| 2014-12-31 | CN¥61.64 Million ≈ $9.02 Million |
+58.85% |
| 2013-12-31 | CN¥38.81 Million ≈ $5.68 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Nanjing Vishee Medical Technology Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1377.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥486.13 Million | 28.71% |
| Other Components | CN¥1.21 Billion | 71.29% |
| Total Equity | CN¥1.69 Billion | 100.00% |
Nanjing Vishee Medical Technology Co Ltd Competitors by Market Cap
The table below lists competitors of Nanjing Vishee Medical Technology Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shenzhen Sunxing Light Alloys
SHG:603978
|
$838.35 Million |
|
United Overseas Australia Ltd
AU:UOS
|
$838.43 Million |
|
Guangxi Wuzhou Communications Co Ltd
SHG:600368
|
$838.53 Million |
|
Jiangxi Sanchuan Water Meter
SHE:300066
|
$838.56 Million |
|
Lian Hwa Foods Corp
TW:1231
|
$837.80 Million |
|
Metro Healthcare Indonesia
JK:CARE
|
$837.78 Million |
|
Cangzhou Dahua Co Ltd
SHG:600230
|
$837.76 Million |
|
Metalurgica Gerdau S.A
SA:GOAU3
|
$837.71 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nanjing Vishee Medical Technology Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,627,462,889 to 1,693,046,126, a change of 65,583,237 (4.0%).
- Net income of 136,632,000 contributed positively to equity growth.
- Dividend payments of 76,569,346 reduced retained earnings.
- Other comprehensive income decreased equity by 47,020,552.
- Other factors increased equity by 52,541,135.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥136.63 Million | +8.07% |
| Dividends Paid | CN¥76.57 Million | -4.52% |
| Other Comprehensive Income | CN¥-47.02 Million | -2.78% |
| Other Changes | CN¥52.54 Million | +3.1% |
| Total Change | CN¥- | 4.03% |
Book Value vs Market Value Analysis
This analysis compares Nanjing Vishee Medical Technology Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.38x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 77.59x to 3.38x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | CN¥0.77 | CN¥59.82 | x |
| 2014-12-31 | CN¥1.23 | CN¥59.82 | x |
| 2015-12-31 | CN¥2.12 | CN¥59.82 | x |
| 2016-12-31 | CN¥2.36 | CN¥59.82 | x |
| 2017-12-31 | CN¥2.03 | CN¥59.82 | x |
| 2018-12-31 | CN¥2.62 | CN¥59.82 | x |
| 2019-12-31 | CN¥3.47 | CN¥59.82 | x |
| 2020-12-31 | CN¥17.20 | CN¥59.82 | x |
| 2021-12-31 | CN¥15.98 | CN¥59.82 | x |
| 2022-12-31 | CN¥15.98 | CN¥59.82 | x |
| 2023-12-31 | CN¥17.00 | CN¥59.82 | x |
| 2024-12-31 | CN¥17.05 | CN¥59.82 | x |
| 2025-12-31 | CN¥17.72 | CN¥59.82 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nanjing Vishee Medical Technology Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.07%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 29.53%
- • Asset Turnover: 0.24x
- • Equity Multiplier: 1.13x
- Recent ROE (8.07%) is below the historical average (20.84%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 36.72% | 28.64% | 0.68x | 1.88x | CN¥10.18 Million |
| 2014 | 35.71% | 37.40% | 0.72x | 1.34x | CN¥15.66 Million |
| 2015 | 26.47% | 34.94% | 0.64x | 1.19x | CN¥17.50 Million |
| 2016 | 19.58% | 24.14% | 0.57x | 1.44x | CN¥11.33 Million |
| 2017 | 28.00% | 27.92% | 0.59x | 1.71x | CN¥25.93 Million |
| 2018 | 33.81% | 30.50% | 0.67x | 1.65x | CN¥44.62 Million |
| 2019 | 40.01% | 31.27% | 0.79x | 1.62x | CN¥74.79 Million |
| 2020 | 10.22% | 37.97% | 0.25x | 1.10x | CN¥3.06 Million |
| 2021 | 11.60% | 41.35% | 0.26x | 1.07x | CN¥24.51 Million |
| 2022 | 6.14% | 29.17% | 0.19x | 1.10x | CN¥-59.03 Million |
| 2023 | 8.38% | 29.48% | 0.26x | 1.11x | CN¥-26.42 Million |
| 2024 | 6.27% | 25.49% | 0.22x | 1.12x | CN¥-60.78 Million |
| 2025 | 8.07% | 29.53% | 0.24x | 1.13x | CN¥-32.67 Million |
Industry Comparison
This section compares Nanjing Vishee Medical Technology Co Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $3,167,552,206
- Average return on equity (ROE) among peers: 15.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nanjing Vishee Medical Technology Co Ltd (688580) | CN¥1.76 Billion | 36.72% | 0.06x | $838.34 Million |
| Shanghai Kehua Bio-Engineering Co Ltd (002022) | $146.21 Million | 21.81% | 0.54x | $368.80 Million |
| Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223) | $12.65 Billion | 14.27% | 0.24x | $3.88 Billion |
| Double Medical Technology Inc (002901) | $3.11 Billion | 2.98% | 0.27x | $2.80 Billion |
| Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) | $2.85 Billion | 49.59% | 0.20x | $503.91 Million |
| Lepu Medical Tech Beijing (300003) | $6.58 Billion | 18.53% | 1.30x | $3.46 Billion |
| INKON Life Technology Co Ltd (300143) | $1.81 Billion | -20.17% | 0.37x | $775.36 Million |
| Edan Instruments Inc (300206) | $1.14 Billion | 5.20% | 0.04x | $1.07 Billion |
| Guangdong Biolight Meditech Co Ltd (300246) | $1.50 Billion | 1.47% | 0.62x | $567.25 Million |
| Beijing Leadman Biochemistry Co Ltd (300289) | $1.80 Billion | 0.85% | 0.07x | $458.53 Million |
| Sinocare Inc (300298) | $91.35 Million | 60.05% | 0.60x | $1.22 Billion |
About Nanjing Vishee Medical Technology Co Ltd
Nanjing Vishee Medical Technology Co., Ltd provides rehabilitation meditation products and solutions in China and internationally. The company offers MagNeuro, a transcranial magnetic stimulation (TMS) for use in anxiety disorders, movement disorders, and ADHD applications; MagNeuro ONE, a TMS therapy system with navigation for use in anxiety disorders applications; and MagBelle, a pelvic floor m… Read more